GlycA for long-term outcome in T2DM secondary prevention

Bernhard Zierfuss, Clemens Höbaus, Carsten T. Herz, Gerfried Pesau, Daniel Mrak, Renate Koppensteiner, Gerit-Holger Schernthaner

Research output: Journal article (peer-reviewed)Journal article

5 Citations (Scopus)


AIMS: Glycosylated acetyls (GlycA), a systemic marker of inflammation, were associated both with incident type 2 diabetes mellitus (T2DM) and incident cardiovascular (CV) disease. This study evaluates the predictive value of GlycA for long-term survival in patients with T2DM and peripheral artery disease (PAD).

METHODS: GlycA (mmol/l) levels were measured by nuclear magnetic resonance spectroscopy in a cross-sectional cohort of patients with PAD (n = 319). Both all-cause and CV mortality were evaluated after a follow-up of 9.0 (IQR 6.5-9.5) years. During the follow-up 117 patients died, of those 64 events were of CV origin (PAD-T2DM subgroup: all-cause mortality n = 60, CV-mortality n = 32).

RESULTS: PAD-T2DM showed a tendency towards a worse CV risk factor profile and a higher percentage of known coronary artery disease (24.9% vs 43.5%, p < 0.001). GlycA levels were higher in PAD-T2DM (1.6 ± 0.2 vs. 1.53 ± 0.18, p = 0.002). GlycA predicted all-cause mortality after multivariable adjustment for traditional CV risk factors (HR for 1 SD increase 1.51, 95% confidence interval 1.03-2.19) in PAD-T2DM, while no association could be seen with CV-mortality (1.22, 0.73-2.06).

CONCLUSIONS: GlycA was capable of predicting long-term outcome in PAD patients with T2DM. Thus, GlycA might reflect the added inflammatory burden of T2DM in systemic atherosclerosis.

Original languageEnglish
Article number108583
JournalDiabetes Research and Clinical Practice
Publication statusPublished - Jan 2021


  • Cohort study
  • Macrovascular disease
  • Mortality
  • Peripheral artery disease
  • Type 2 diabetes
  • Cross-Sectional Studies
  • Humans
  • Middle Aged
  • Male
  • Glycosylation
  • Magnetic Resonance Spectroscopy/methods
  • Peripheral Arterial Disease/diagnosis
  • Secondary Prevention/methods
  • Diabetes Mellitus, Type 2/mortality
  • Survival Analysis
  • Aged, 80 and over
  • Adult
  • Biomarkers/blood
  • Female
  • Aged

ASJC Scopus subject areas

  • Endocrinology
  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism


Dive into the research topics of 'GlycA for long-term outcome in T2DM secondary prevention'. Together they form a unique fingerprint.

Cite this